¦æ
¬F°|°ê
®a¬ì
¾Ç
©e-û
·|±MÃD¬ã
¨s-pµe¦¨
ªG³ø
§i
°ê
¤HªÍ
¸¢
Àù
¤§
°ò
¦
»PÁ{§É
‹
¨s¡Ð
ÂH²G¯À
³J¥Õ
ªí
²{»PªÍ
Àù
¤§
Ãö
«Y
Mucins and Lung Cancer
-pµe½s¸¹
¡GNSC88-2314-B-002-083-M39
°õ
¦æ
´Á
--
¡G¦Û
¥Á
°ê
87¦~
08¤ë
01¤é
°_¦Ü
¥Á
°ê
88¦~
07¤ë
31¤é
¥D«ù
¤H¡G§E©¾
¤¯
°õ
¦æ
¾÷
ºc¤Î
³æ
¦ì
¦WºÙ
¡G¥x¤jÂå
¾Ç
°|¤º
“
-pµe¤¤
¤å
ºK-n
ªñ´X¦~¨Ó¡AÂH²G¯À»PÀù¯g¤§ÃöÁp©Ê¤w ³vº¥³QÁA¸Ñ¡CÂÇ¥ÑÂH²G¯À³J¥Õ¤ÎÁޤƹLµ{ ¤§²§±`ªí²{¡AÀù²Ó-M¸û©ö«I¤J¦å²G´`Àô¡A °kÁ×±J¥D¤§§K¬Ì§ðÀ»¨t²Î¡A¦Óµo¥Í»·³BÂà ²¾¡C§Ú-̤§«e±q¨ÆªÍÀùÂH²G¯À¤§¬ã¨s¡Aµo ²{ªÍÀù¡A¤×¨ä¬OªÍ¸¢Àù¤§²CÂH²G¯À ¡]sialomucin¡^ªí²{»PÀùªº³N«á¦Aµo¤ÎÀù¦º ¤`¦³Ãö¡A¦ÓMUC5AC °ò¦]¤§ªí²{»PªÍ¸¢ Àù²Õ´«¬¤Î²CÂH²G¯Àªí²{¦³Ãö¡C¦]¦¹¡A Muc5AC ¤§³J¥Õ»P°ò¦]ªí²{¤§±´°Q¡A¬°ªÍ Àù¬ã¨sªº-«ÂI¤§¤@¡C¥»-p¹ºÀÀ¶°¤¤©ó¬ã¨s MUC5 ÂH²G¯À³J¥Õ¦bªÍÀùªí²{¤§-«-n©Ê¡C §Ú-̧Q¥Î¿ï´Ó¤§Muc5AC cDNA «D-«ÂФù ¬q¡A»s³y20KD ¤§Muc5AC ¿Ä¦X³J¥Õ¡A¥´ ¤J°Êª«¡]Âû¤Îø{¹«¡^Å餺¡A»s³Æ¥X¦h·½¤Î ³æ·½§ÜÅé¡A¨Ã¹Á¸ÕÀ³¥Î©ó²Õ´ÀËÅ餧§K¬Ì ²Õ´¤Æ¾Ç¬V¦â¡A¦è¤è¾¥ÂIªk¡A¯f¤H¦å²G¡B Åé²G¤§ELISA¡Aµo²{¨äµ²ªG¨Ã¤£²z·Q¡C ÃöÁäµü¡GÂH²G¯À³J¥Õ¡BÂH²G¯À°ò¦]¡B³æ·½ §ÜÅé¡B¦h·½§ÜÅé¡BªÍÀù-pµe-^¤å
ºK-n
Aberrant expression of mucins and mucin related antigens are noted to be poor survival factors in cancer. Experimentally, mucins had been demonstrated to promote tumor cell invasion, metastasis and
modulate the immune recognition phenomenon of cancer cells. Only few studies have addressed the prognostic implications of mucin and mucin associated antigens in lung cancer. Our previous investigations had discovered the association among lung adenocarcinoma, sialomucin and Muc5AC expression. Therefore, to study the regulation of Muc5AC protein expression should be an important topic in investigating lung cancer. In order to study the protein expression of Muc5AC in lung cancer, 20 kD fusion protein of Muc5AC nontandem repeat sequence was made, injected into animals (chicken, and mice), and successfully generated anti-Muc5AC polyclonal and monoclonal antibodies. These antibodies were applied in the immunohistochemistry, western blotting of variable specimens of lung cancer, as well as ELISA assay. The results are unsatisfactory.
Keywords¡GMucin glycoprotein, mucin gene, monoclonal antibody, polyclonal antibody, lung cancer
¡@¡@¼Æ¤Q¦~¨Ó¡A¥þ¥@¬ÉªºªÍÀù±wªÌ«ùÄò¼W ¥[[1]¡C¦b¥xÆW¦a°Ï¡AªÍÀùªºµo¥Í²v»P¦º¤` ²v¡A¤£½×¨k¤k¡A§¡§Ö³t¼W¥[¤¤¡Cªñ¤-¤Q¦~ ¨Ó¡A¥xÆW¦a°Ï¨k¤kªÍÀù¦º¤`²v¼W¥[ªº³t «×¡A¬O¥þ¥@¬É³Ì§Öªº¡A¦Ó¥xÆWªÍÀù»P¥@¬É ¨ä¥L¦a°Ï¤£¦Pªº¬O¡A¨k¤k¤ñ¨Ò¤£°ª¡A¬ù¬° 1.6-2.0 ¤ñ1¡A§lµÒÃø¥H§¹¥þ¸ÑÄÀªÍÀù¦¨¦] (¤k©ÊªÍÀùªñ85%µLªk¥H§lµÒ¨Ó¸ÑÄÀ¡^¡A¦Ó ¥B¦bªÍÀù¥D-nªº¥|-Ó²Õ´«¬¤¤¡A¸¢Àùªº¤ñ ¨Ò¸û¦è¤è°ê®a¬°°ª (¨k©Ê¥e36.5%¡A¤k©Ê ¥e58.7%) [2]¡C ¡@¡@ªÍÀù³y¦¨°ª¦º¤`²vªº-ì¦]¦b©ó¡G(1) ¶EÂ_¤£©ö¦-´Á½T¥ß¡F(2)¥i¶}¤M¤Á°£ªº¤ñ¨Ò ¤£°ª¡F(3)³N«á´_µo¾÷·|°ª¡F(4)¤£¯à¶}¤Mªv Àøªº¸~½F¡A¹ï¨ä¥LªvÀø¡A¦p¤Æ¾ÇÀøªk©Î©ñ ®g½uÀøªk¤§¤ÏÀ³¥ç¤£¨Î¡C¨ä¤¤¡A¦b¥xÆW¥e °ª¤ñ¨ÒªºªÍ¸¢Àù¡A¨ä¯S¼x¬°¦-´ÁÂಾ(¸~½F ¤j©ó¤G¤½¤À«á¡A»·³BÂಾ¥i¯à©Ê¤j¼W)¡A³N «á©ö¦Aµo¡A¹w«á¸ûÅ쪬¤W¥ÖÀù¬°®t [3]¡C ¦ÓÂH²G¯Àªí²{¬°¸¢Àù¯S¼x¤§¤@¡C¸g¥Ñ¨ä¥L Àù¯g (¦p¤j¸zÀù)¤§¬ã¨sÅã¥ÜÂH²G¯À¤§ªí ²{¥i¯à¬°Àù¯gÂಾ¤§-«-n¦]¤l¡A¦]¦¹§Ú-Ì ¹ïªÍÀù²Õ´¤§ÂH²G¯Àªí²{¶i¦æ¤@³s¦êªº¤À ªR¡C¥D-nªº±´°Q¡A¥]¬A (1)¦³ÂH²G¯Àªí²{ ªºªÍÀù¡A¬O§_¯uªº¹w«á¸û®t¡H (2) ÂH²G¯À °ò¦]¦bªÍÀù¤§ªí²{¬O§_·|¦³²§±`¡A¨ä²§±` ¤§°ò¦]«¬¤À§G¦p¦ó¡H¨ä°ò¦]ªí²{²Õ¦¨¬O§_ ¦³¤£¦P¡H (3) ÂH²G¯À°ò¦]¤§ªí²{Åܲ§¦³ µL¥ô¦óÁ{§É¤Wªº·N¸q¡H»P¯f¤H¹w«á¬O§_¬Û Ãö¡H §Ú-Ì¥ý«eªº¬ã¨s§Q¥Î¤w«Ø¥ß¤§ªÍÀù ²Ó-M®è¤Îªø®É¶¡¦¬¶°¤§ªÍÀùÀËÅ鬰§÷ ®Æ¡A¥H²Õ´¤Æ¾Ç¬V¦âªk¡B§K¬Ì²Õ´¤Æ¾Ç¬V ¦âªk¡B¥_¤è¾¥ÂIÂø¥æªk¡B±øª¬¾¥ÂIÂø¥æ ªk¡B¤ÎÄvª§©w¶q¦¡®Ö»Ä»E¦X±öÃì¤ÏÀ³¨ÓÀË ´úÂH²G¯À°ò¦]ªí²{»PªÍÀù¤§Ãö«Y¡C µ²ªG Åã¥Ü¡G¡]1¡^§Q¥Î²Õ´¤Æ¾Ç¬V¦âªk¤Î§K¬Ì²Õ ´¤Æ¾Ç¬V¦âªk¡Aµo²{ªÍÀù¡A¤×¨ä¬OªÍ¸¢Àù
¤§²CÂH²G¯À¡]sialomucin¡^ªí²{»PÀùªº³N«á ¦Aµo¤ÎÀù¦º¤`¦³Ãö[4]¡C¡]2¡^§Q¥Î±øª¬¾¥ÂI Âø¥æªk¡A¤ñ¸ûªÍÀù»P«DªÍÀù²Õ´¤¤¡A¼ÆºØ ÂH²G¯À°ò¦]ªí²{¶q¡]Muc1-4, -5AC, -5B¡^¡A ¥iµo²{Muc5AC ¤ÎMuc5B ¤§¹L«×ªí²{¡A »PªÍÀù¹w«á©úÅV¬ÛÃö[5]¡C¡]3¡^¹B¥ÎÄvª§¦¡ ®Ö»Ä»E¦X ³sÂê¤ÏÀ³¡A©w¶qMuc1, 2, -5AC ¤§mRNA ªí²{¶q¡A¥iµo²{Muc5AC ªí²{»PªÍ¸¢Àù²Õ´«¬¤Î²CÂH²G¯Àªí²{¦³ Ãö[6]¡C ¥»-pµe§Q¥ÎMuc5AC ¿Ä¦X³J¥Õ¤Î¦X ¦¨¤§ Ãì(«D-«ÂФù¬q°Ï)¡A«Ø¥ß Muc5AC ÂH²G¯À¤§¦h·½(polyclonal)¤Î³æ·½ (monoclonal)§ÜÅé¡A¬ã¨s¨ä¹B¥Î©óÁ{§ÉÀËÅé ¬ã¨s(¦p²Õ´¤§§K¬Ì²Õ´¤Æ¾Ç¬V¦â¤Î¦å ²M¡BÅé²GÀËÅéELISA)¤§¥i¦æ©Ê¡C
‹
¨s¤è
ªk
¿Ä¦X³J¥Õªºªí²{ ¿ï´Ó©óPGEM-T ¸üÅ餧Muc5AC cDNA ¤ù¬q¥HApa I --¨î ¤Á¤U¡A¥HDNA ±µ¦X×Q±µ¶ipRSETA, pRSETB ¤ÎpRSETC ¤T-Ó¤£¦Pcloning frame ½èÅé(Invitrogen) ¤¤¡AÂà¤JJM109 ªº³Ó¥ô²Ó-M¡C¥H IPTG »¤ ¾É°ò¦]-«²Õ³J¥Õªºªí²{¡AµßÅé·»¸Ñ«á¡A©ó 5% - 20% gradient SDS-PAGE ¹qªa¨Ã¥H Coomassie blue ¬V¦â¡C¿ï¾Ü·|ªí²{·s³J¥Õ ¤§µß®è¡CSDS-»E¤þ²mñQÓi½¦¹qªa
Resolving gel ªº¿@«×¿ï¥Î¬°15%¡A¹q ªa«e±N±ý´ú¸Õªº³J¥Õ¼Ë«~·»¸Ñ©ó2 X sample buffer¡A©ó¤ô¯D¤¤µNªm5 ¤ÀÄÁ«áª` ¤Jgel ¤§¥W¼Ñ¤¤¡A¦b1x Tris-glycine
electrophoresis buffer ¤¤¥HÃ-©w¤§¹qÀ£¹qªa ¦Ü«ü¥Ü¬V¾¯¨ì¹F»E¤þ²mñQÓi½¦ªº©³ºÝ¡C¤p ¤ß¨ú¤U»E¤þ²mñQÓi½¦©óCoomassie blue staining solution ¬V¦â¬ù1 ¤p®É¡A¦A¥H destaining solution ¥h¬V¦â¡A±Ngel ©ó¯uªÅ
¯M°®¾÷¯M°®¡C ¿Ä¦X³J¥ÕªºµÑ¨ú
¥ÑSDS-PAGE µ²ªG¬D¿ï¥X·|ªí²{¿Ä ¦X³J¥Õµß®è¤j¶q°ö¾i¡A¨Ã¥HIPTG »¤¾É¿Ä ¦X³J¥Õ¡A¥HNi++ charged column ¯Â¤Æ³J
¥Õ¡A¹qªa«áªº»E¤þ²mñQÓi½¦¥H0.1%
Coomassie blue ¬V¦â¬ù30 ¤ÀÄÁ«á¡A¥H¤ô²æ ¦â¬ù30 ¤ÀÄÁ¦Ü1 ¤p®É¡Aª½¨ì¿Ä¦X³J¥Õªº band ¥i¥H¿ëÃÑ¡A¤p¤ß±Nband ¤Á¤U¡A©ó Model 422 Electro-Eluter (Bio-Rad) ¤¤¥H Ã-©w¹q¬y(8mA x ºÞ¼Æ)±N³J¥Õ¥Ñ»E¤þ²mñQ Ói½¦´åÂ÷¥X¨Ó¡C·»²G¥H6 -¿Åé¿nªºacetone ·»²G©ó-20¢J1 ¤p®É±N³J¥Õ¨H¾ý¡A¦b-«ÂФ@ ¦¸«á¡A¨H¾ýª«¥H70%°sºë¬~¤@¹M¡AµM«á¥H ¤ô·»¸Ñ¡C¸gCentricon-10 (Amicon)¥hÆQ«á ´«¦¨¥Í²z-¹ÆQ¤ô·»²G¡A¥Hprotein assay kit (Bio-Rad)´ú¶q³J¥Õ½è¿@«×¡C
¦h·½§ÜÅé¦å²Mªº»s³Æ
¨ú¬ù200 µg «e-zªº¿Ä¦X³J¥Õ»Pµ¥Åé ¿n¤§Freund complete adjuvant ¥Hsonicator ²V¦X¦¨½¦ª¬(¬ù1ml)¡A¤À§O¥´¤J¥|°¦¤w©â ¨ú¥¼§K¬Ì³J²M¤§22-24 ¶g¤j¤§Âû¡A¨C¹j¥| ¶g¤@¦¸boost (100 µg)¡A³sµ¹¤T¦¸«á¡A¦b¹j ¤-¤Ñ«á¨ú³J¡A³J²M¸m©ó-20¢J¤¤¡C
¿Ë©M©Ê¼hªRªk(Affinity chromatogr aphy) ¯Â¤Æ¦h·½§ÜÅé
Muc5AC ±µ¤W(coupling) CNBr activated-Sepharose 4B column
(Pharmacia)¡C¸g¿Ä¦X³J¥Õ§K¬Ì¤§¨ß¦å²M©Î Âû³J¶À¥H0.01M Tris HCl (pH7.6) °µ¤Q-¿ µ}ÄÀ«á¡A¦b©ópeptide-sepharose column §@ ¤À¼h¡A³Ì«á¥H0.01M Tris-HCl¡A0.5M NaCl (pH7.6)¬~§¹«á¦A¥H0.1M glycine (pH 2.5) µÑ¨ú§ÜÅé¡A¨Ã°¨¤W¥H1M Tris ¤¤©M¡C±µµÛ ¥HELISA ´ú¸Õ§ÜÅ餧±M¤@©Ê¡C
³æ·½§ÜÅé¤Î¿Ä¦X½F¤§»s³Æ
¨ú¬ù100 µg ·»©ó¥Í²z-¹ÆQ¤ô¤§¿Ä¦X ³J¥Õ»Pµ¥Åé¿n¤§Freund complete adjuvant
¥Hsonicator ²V¦X¦¨½¦ª¬(¬ù1 ml)¡A¥Ö¤º¦h ³Bª`®g©ó4-6 ¶g¤j¤§BALB/c ø{¹«¡C2-3 ¶g«á¡A¦A¦¸¥Ö¤ºª`®g¡C¦A¸g2 ¶g«á¡A¥Ñ§À ÀR¯ßª`¤J50 µg ·»©ó¥Í²z-¹ÆQ¤ô¤§³J¥Õ©Î ±µ¦X ¡A©ó3 ¤é«á¨ú¨äµÊŦ§@¬°»s³Æ¿Ä ¦X½F¤§¥Î¡C §K¬Ì´ú©wªk(ELISA) ¨ú5-10 µg ¤§¿Ä¦X³J¥Õ©Î±µ¦X¬¹¨O·» ©ó10 ml ªº0.05 M ºÒ»ÄÆQ·»²G¤¤(pH 9.6)¡A©ó96 ¤Õ¤§·L¶q´ú©w½L¤W¡A¨C¤Õ¥[¤J 0.1 ml¡A¦Ü©ó42¢J¤§·Å½c¤¤§@¥Î2 ¤p®É¡A §l±¼¤W²M²G¡A©ó¨C¤Õ¤º¥[¤J0.125ml ªº 0.1% BSA ·»©óPBS¡A¸g©ó37¢J¤§·Å½c¤¤ §@¥Î1 ¤p®É«á¥H¬~º°²G¬~3 ¦¸¡A¦b¥[¤J 0.1ml «Ý´ú¤§¿Ä¦X½F°ö¾i²G¡A©ó37¢J¤¤§@ ¥Î1 ¤p®É«á¥Î¬~º°²G²M¬~3 ¦¸¡A¦A¥[¤J¹L ®ñ¤Æ ¼Ð¥Ü¤s¦Ï§Üø{¹«§K¬Ì²y³J¥ÕG¡A37 ¢J¤¤§@¥Î1 ¤p®É¸g¥H¬~º°²G²M¬~3 ¦¸«á¥[ ¤J¹L®ñ¤Æ ¨ü½è§e¦â²G0.1 ml¡A¦ÜÃC¦âÅã ¥X«á¥H1:8 ¤§°ª¿@«×²¸»Ä¤ô·»²G0.1ml °± ¤î¤§¡A¥H¥Øµø¬ãŪµ²ªG¡C ¦è¤è¾¥ÂI¸ÕÅç ¨úªÍ²Õ´¤â³NÀËÅé©â¨ú¤§³J¥Õ½è¡B©I §l¹D¤W¥Ö²Ó-M°ö¾i²G¡B©I§l¹D¤W¥Ö²Ó-MµÑ ¨ú²G¡A¶i¦æ»E¤þ²mñQÓi½¦¹qªa¡A¹qªa«áªº »E¤þ²mñQÓi½¦Âàº{¨ìNitrocellulose
membrane¡Cmembrane ®û©ó5% skim milk 30 ¤ÀÄÁ¡A¦A¥[¤J¥HPBS µ}ÄÀ1000X Åé¿n ªº¥¼§K¬Ì¦å²M©Î§ÜÅé¡A©ó 4¢J§@¥Î¦Ü¹j ¤Ñ¡A¥H0.1 % PBS-T ²M¬~3 ¦¸¡A¨C¦¸5 ¤À ÄÁ¡C¦A»P¥HPBS µ}ÄÀ1000 -¿Åé¿n¤§HRP conjugated anti-rabbit IgG ©ó37¢J§@¥Î1 ¤p ®É¡C¦P¤Wªk²M¬~«á¡A¥H4-chloro-1-naphthol ¤Î10 ml 30% H2O2 §@§e¦â¤ÏÀ³¡C
µ²
ªG
´Ó¤JpRSETC-MUC5AC ¸üÅ餧 JM109 µß®è¡Aªí²{MUC5AC «D-«ÂФù¬q
¤§¿Ä¦X³J¥Õ¡C¡]¹Ï¤@¡^ ¦h·½§ÜÅé¦å²Mªº»s³Æ
¨ú¬ù200 µg ªº¿Ä¦X³J¥Õ²V¦Xµ¥Åé¿n ¤§Freund complete adjuvant¡A¥´¤JÂû ¨-¤W¡A³sµ¹¤T¦¸boost «á¡A¹j¤-¤Ñ«á¨ú³J¡A ³J²M¸m©ó-20¢J¤¤¡C¸g¿Ë©M©Ê¼hªRªk¯Â¤Æ¡A ¿ï¥XMUC5AC ¤§¦h·½§ÜÅé¡]¹Ï¤G¡^¡C ³æ·½§ÜÅ餧»s³Æ §Q¥ÎMUC5AC -«ÂФù¬q¤§¦X¦¨ Ãì±µ¦X¤WKLH «á¥´©óø{¹«¨-¤W¡A¥¼¯à²£ ¥Í¨ãMuc5AC ¯S²§©Ê¤§§ÜÅé¡C¦Ó§Q¥Î«D-« ÂФù¬q¤§¿Ä¦X³J¥Õ«h¶¶§Q»s³y¥X¤E®èø{ ¹«¤§³æ·½§ÜÅé¡]¹Ï¤T¡^¡C Muc5AC §ÜÅé¹ï²Õ´¤ÎÁ{§ÉÀËÅé§@¦è¤è ¾¥ÂI¸ÕÅç¡B²Õ´¬V¦â¤ÎELISA ¤§¥i¦æ©Ê
¨úªÍ²Õ´¤â³NÀËÅé©â¨ú¤§³J¥Õ½è¡B©I§l¹D ¤W¥Ö²Ó-M°ö¾i²G¡B©I§l¹D¤W¥Ö²Ó-MµÑ¨ú ²G¡B¿Ä¦X³J¥Õ¤Î¦X¦¨ ¬°§Ü-ì¡A¥H17Q2 ¤Î§ÜMuc5AC -«ÂФù¬q¤§³æ·½§ÜÅé (CLH2)¬°positive control¡Cµo²{¥»¬ã¨s©Ò »s³Æ¤§§ÜÅé¦b¦è¤è¾¥ÂI¸ÕÅç¡B²Õ´¬V¦â¤Î ELISA ªº±Ó·P«×¤Î¯S²§©Ê¤£¦p17Q2 ¤Î CLH2¡C
°Q½×
¥»¬ã¨s©Ò»s³Æ¤§§ÜÅé®Ä¯à¤£¨Î¤§¥D¦]¥i ¯à¬°©Ò¿ï¾Ü¤§§Ü-ì¦ì¸m¬°ÁޤƲ{¶H©Ò¾B »\¡A¦ÓÂH²G¯À¤§«D-«½Æ¤ù¬q¤§§Ü-ì©Ê¤£¦p -«½Æ¤ù¬q¨Ó±o±j¡A¥ç¬°¥i¯à¤§-ì¦]¡C°Ñ
¦Ò
¤å
Äm
1. Parkin D.M., Pisani P., and Ferlay J. 1993. Int. J. Cancer 54:594-606.
2. Luh K.T., and Chang D.B. 1992. J. Formosan Med. Assoc. 91(suppl l):Sl-S7. 3. Sagawa M., Saito Y., Takahashi S., et al.
1990. Cancer 66:2653-2657.
4. Yu C.J., Shun C.T., Yang P.C., et al. 1997. Am. J. Respir. Crit Care Med. 155:1419-27.
5. Yu C.J., Yang P.C., Shun C.T., et al. 1996b. Int. J. Cancer (Pred. Oncol.) 69:457-65.
6. Yu C.J., Shew J.Y., Shun C.T., et al. 1998. Am. J. Respir. Cell Mol. Biol. 18: 643-652.
